Analyst Research Report Snapshot


ADMA: 1Q14: RI-002 study is on track with plasma collection center expansion underway; reiterating with Buy rating and $15 price target




Laidlaw & Company


14 May 2014





Companies referenced:


Available for Immediate Download

ADMA recently reported 1Q14 financial results with a net loss of ($5.9MM), or ($0.64) net loss per share. With cash of ~$28.7MM by the end of 1Q14, we believe the company has sufficient capital for operations entering 2016. ADMA indicated that the Phase III study has advanced into its half way mark as >70% of expected infusions to patients have taken place; while some patients have already completed the entire dosing. RI-002 could potentially be used off-label for RSV infection management in PIDD and transplant patients should it receive approval as a regular IVIG with high titer of anti-RSV antibodies. In our opinion, if approved, RI-002 could be very appealing to more vulnerable patients given the lack of suitable products in market. In addition, ADMA shares are eligible to be up-listed to the NASDAQ market by 4Q14. Such development, in our opinion, potentially could further expand institutional investor base and gain greater visibility.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.